Topline data were announced from a phase 3 trial that evaluated baxdrostat in patients with uncontrolled or treatment resistant hypertension.

AstraZeneca AZN reported positive top-line results from a late-stage study evaluating the safety, tolerability and efficacy ...

AstraZeneca announced that baxdrostat, a selective aldosterone synthase inhibitor, met its primary and all secondary ...

In a new clinical practice guideline, the Endocrine Society advises universal screening of those with hypertension by ...

David’s blood pressure was dangerously high until he received specialized care and renal denervation at BIDMC’s Complex Hypertension Clinic. Read his story.

At two doses, baxdrostat demonstrated significant reduction in mean seated systolic BP vs. placebo at 12 weeks among patients ...

The scope of resistant hypertension has not been quantified, but clinical trials suggest it may affect up to 30 percent of people with high blood pressure.

AstraZeneca's Phase 3 trial showed baxdrostat lowered systolic blood pressure in treatment-resistant hypertension with a ...

In addition to taking medication, paying attention to these habits can help maintain healthy blood pressure levels..resistant ...

“Baxdrostat BaxHTN Phase III trials on patients with uncontrolled or treatment-resistant hypertension demonstrated a ...

Struggling to control high BP? Learn about resistant hypertension, its causes, and expert-approved ways to manage it. Get ...

AstraZeneca said on Monday its experimental drug baxdrostat significantly lowered blood pressure in a late-stage trial of ...